Table 3.
Demographic and clinical features of the enrolled patients with macrophage activation syndrome (MAS)
| Clinical features | |
|---|---|
| Number of patients | 13 |
| Women/men | 7/6 |
| Age (years), mean ± SD | 52.02 ± 19.01 |
| Triggering factor | |
| AOSD flare, number (%) | 13 (100) |
| Lymphoma, number (%) | 0 |
| Infectious disease, number (%) | 0 |
| Laboratory features | |
| WBC (103/mL), mean ± SD | 3.28 ± 1.36 |
| RBC (103/mL), mean ± SD | 3.31 ± 0.69 |
| HB (gr/dL), mean ± SD | 9.19 ± 2.05 |
| PLT (103/mL), mean ± SD | 55.52 ± 46.54 |
| Serum Ferritin (ng/mL), mean ± SD | 4362.15 ± 7569.70 |
| ESR (mm/hour), mean ± SD | 71.23 ± 30.19 |
| CRP (mg/L), mean ± SD | 74.76 ± 46.92 |
| Triglycerides (mg/dL), mean ± SD | 183.12 ± 69.33 |
| ASAT (IU/L), mean ± SD | 74.59 ± 41.89 |
| ALAT (IU/L), mean ± SD | 129.98 ± 91.21 |
| Treatments | |
| High dosage steroid pulses, number (%) | 13 (100) |
| Immunosuppressive drugs, number (%) | 7 (53.84) |
| Cyclosporine A, number (%) | 5 (38.46) |
| Methotrexate, number (%) | 2 (15.38) |
| Etoposide | 0 |
| Biologic drugs | 2 (15.38) |
| Deaths, number (%) | 10 (76.92) |
| Number of relapses in MAS-survivors patients, mean ± SD | 2.66 ± 1.69 |
AOSD adult-onset Still’s disease, IU international unit, WBC white blood cell count, RBC red blood cells, HB hemoglobin, PLT platelet count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ASAT aspartate aminotransferase, ALAT alanine aminotransferase